In this CE activity, experts in the field evaluate the latest evidence-based treatment strategies for patients with neovascular age-related macular degeneration (nAMD), examine clinical trial data for emerging therapies, and assess treatment options for patients with geographic atrophy secondary to AMD based on current clinical evidence.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Address:
- 6900 Grove Road
Pricing
100% of listed courses are free
256 of 256 courses listed here are free.
Collected from the provider’s public pages · source
Specialties served/covered
- Adolescent Medicine
- Allergy & Clinical Immunology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- General Internal Medicine
- General Operative Anesthesia
- General Otolaryngology
- General Pediatrics
- Infectious Disease
- Medical Oncology
- Metabolic & Bariatric Surgery
- Mood & Anxiety Disorders
- Nephrology
- Neurology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Practice Management & Ethics
- Psychopharmacology
- Psychotic Disorders
- Pulmonary Disease
- Rheumatology
- Rhinology
- Anesthesiology
- Cardio-Vascular
- Cross-Specialty
- ENT & Head Neck
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Oncology & Hematology
- Pediatrics
- Primary care
- Psychiatry
- Radiology
- Surgery
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Enduring / On-demand
- Credit · Up to 1.75 credits
- Commercial Support
-
ReleasedDec 31, 2025
-
Last day to claim creditDec 31, 2026 3 months left
-
Med Learning Group Optimizing Outcomes in nAMD: Evidence-Based Selection, Sequencing, and Durability Strategies with Next-Generation Anti-VEGF Therapies
-
Physicians’ Education Resource (CME Track) Reducing Treatment Burden in Retinal Disease Care With Extended-Duration Anti-VEGF Therapies
-
Paradigm Medical Communications, LLC Imaging-Based Retinal Decision-Making in the Era of Second-Generation Therapy
